We have 3 of 20 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
These findings provide clinical evidence for the early diagnosis and risk stratification of Osimertinib resistance, and suggest that targeting the LINC00511-PERK-Nrf2 axis may become a novel therapeutic strategy for restoring drug sensitivity.
A CRABP2/RA/NF‑κB axis that drives LUAD progression is established, highlighting this pathway as a potential therapeutic target for intervention in LUAD.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
